AOA Dx Inc is a biotech company focused on early-stage cancer detection. AOA partnered with a leading oncology researcher at McGill University to develop the first early-stage ovarian cancer liquid biopsy diagnostic test. The co-founders have worked together for the last decade at two previous startups in the women’s health space, both resulting in successful exits upon commercialization. Ovarian cancer is the deadliest gynecological disease because there is no accurate testing method and its symptoms are continuously mistaken for benign conditions, making it incredibly difficult to diagnose the disease in the early stages. Early diagnosis will reduce patient mortality and deliver cost savings to payers.
AOA, a Y combinator and VC backed company, raised a $2.5M Seed Round to accelerate development and clinical studies.
Awards & Accelerators:
1. Y Combinator
2. Springboard Enterprises
3. MassMedic Ignite
4. Massachusetts Life Sciences Center MassNextGen Award
5. The Wave Summit's Emerging Women Founder in Bio Award
www.aoadx.com
AOA, a Y combinator and VC backed company, raised a $2.5M Seed Round to accelerate development and clinical studies.
Awards & Accelerators:
1. Y Combinator
2. Springboard Enterprises
3. MassMedic Ignite
4. Massachusetts Life Sciences Center MassNextGen Award
5. The Wave Summit's Emerging Women Founder in Bio Award
www.aoadx.com
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $26.5M
Founded date: 2019
Investors 20
Show more
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.10.2023 | - | $17M | - |
| 14.09.2022 | - | $7M | - |
| 28.06.2021 | Seed | $2.5M | - |
Mentions in press and media 11
| Date | Title | Description |
| 12.10.2023 | AOA Dx Raises $17M in Funding | AOA Dx, a NYC-based company developing a detection test for ovarian cancer, raised $17M in funding. The round was led by Good Growth Capital with participation from RH Capital, Y Combinator, Astia Fund, Adaptive Capital Partners, Gore Range... |
| 17.08.2023 | The 30 young leaders who are forging a new future for the healthcare industry in 2023 | Your browser does not support the video element. This story is available exclusively to Insider subscribers. Become an Insider and start reading now. A new generation of leaders is transforming the healthcare industry. They're developing ne... |
| 13.09.2022 | AOA Dx Closes $7 Million Funding Round To Bring The First Accurate Early Detection Test For Ovarian Cancer To Market | AOA teamAOA |
| 19.05.2022 | 3 things to remember when diversifying your startup’s cap table | Oriana Papin-Zoghbi Contributor Share on Twitter Oriana Papin-Zoghbi is the CEO and co-founder of AOA Dx, which is developing a non-invasive ovarian cancer diagnostic biopsy test. Making purposeful decisions on diversity and inclusion in th... |
| 11.01.2022 | Three Things To Consider When Searching For The Right Co-Founders | By Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx. |
| 30.09.2021 | AlleyCorp Launches $100M Healthcare Venture Fund for NYC Early-Stage Digital Health Startups | What You Should Know: – AlleyCorp, a NYC firm dedicated to founding, funding, and building transformative companies across industries today announced the launch of the AlleyCorp Healthcare Fund, an $100M early-stage venture capital healthca... |
| 14.09.2021 | 6 компаний Femtech, c летнего набора (S21) Y Combinator | Привет! Меня зовут Маша и я CEO Femtech стартапа Mami.chat. Мне всегда интересно всегда узнать, какие стартапы в сфере женского здоровья прошли отбор. Нашла несколько Femtech стартапов и сейчас расскажу вам о них. 16 16 комментариев 1338 пр... |
| 31.08.2021 | Here are all the companies from Y Combinator’s Summer 2021 Demo Day, Part 1 | Today Y Combinator kicked off the Demo Day cycle for its Summer 2021 cohort. The collection of early-stage startups on day one-of-two alone numbered in the hundreds, meaning that we had to assemble a team here at TechCrunch just to cover it... |
| 28.06.2021 | Y Combinator-backed AOA Raises $2.5 Million In Seed Funding To Develop First Non-Invasive Test Set To Revolutionize The Future Of Ovarian Cancer Diagnostics | AOA's inaugural product is AKRIVIS GD test, a blood test to diagnose women with ovarian cancer earlyAOA |
| - | AOA | - |
Show more